Tirosint Cost in Mississippi 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is Tirosint and Why Does It Cost More Than Standard Levothyroxine?

Tirosint is a brand-name levothyroxine sodium gel capsule manufactured by IBSA Institut Biochimique SA. The formulation contains only four inactive ingredients: gelatin, glycerin, water, and glycol, making it one of the purest oral levothyroxine products on the US market. Standard levothyroxine tablets typically contain calcium phosphate, talc, acacia, and other excipients that can impair absorption in certain patient populations. That formulation difference explains both the clinical rationale for prescribing it and the price premium over generic tablets, which can cost as little as $4 to $12 per month at major pharmacy chains.

The FDA regulates levothyroxine products as drugs with a narrow therapeutic index. Small differences in bioavailability produce clinically meaningful changes in TSH, which is why the FDA issued a guidance specifically addressing levothyroxine bioequivalence standards. Tirosint's gel capsule was reviewed under those standards and carries its own approved labeling. Tirosint FDA prescribing information is available at the FDA accessdata portal.

A 2014 study by Vita et al. published in Endocrine (N=33 patients with post-surgical hypothyroidism and concomitant proton pump inhibitor use) found that switching from levothyroxine tablets to the gel capsule formulation normalized TSH in patients whose TSH had remained elevated on equivalent tablet doses. The full study is indexed on PubMed. That trial directly supports prescribing Tirosint when tablet absorption is suspected to be inadequate.

The narrow therapeutic index designation also means that substituting between formulations without re-checking TSH at 6 to 8 weeks carries real clinical risk, as documented in the American Thyroid Association guidelines on hypothyroidism management.

Tirosint Cash Price in Mississippi in 2026

The retail cash price for Tirosint in Mississippi averages $230 per month for a 30-day supply in 2026. That figure reflects the IBSA manufacturer list price and is consistent across major Mississippi retail chains including Walgreens, CVS, and Walmart when no insurance or discount card is applied.

Price varies slightly by dose strength. Lower-microgram doses (25 mcg, 50 mcg) are priced similarly to higher strengths (125 mcg, 137 mcg, 150 mcg) because the cost driver is the gel capsule technology, not the active-ingredient quantity. A 90-day supply runs approximately $670 to $690 at most Mississippi pharmacies, depending on the dispensing fee applied.

GoodRx and similar pharmacy discount aggregators list Tirosint at $210 to $225 per month at certain Mississippi zip codes when a coupon is applied, though these coupons cannot be combined with insurance or with the IBSA manufacturer savings card.

For comparison, generic levothyroxine sodium tablets (Synthroid equivalent) at 100 mcg cost approximately $15 to $25 per month on GoodRx in Mississippi. The price differential, therefore, is approximately $200 per month. Patients who switch to Tirosint for a documented clinical reason, such as persistent TSH elevation despite adequate tablet doses or a confirmed malabsorption condition, may find that cost the central obstacle to adherence.

The FDA's drug pricing transparency resources and the National Library of Medicine DailyMed database both confirm that no generic gel capsule formulation of levothyroxine had received FDA approval as of the 2025 review date of this article, leaving Tirosint without direct generic competition in the gel capsule category.

Does Mississippi Medicaid Cover Tirosint?

Mississippi Medicaid does not cover Tirosint as of 2026. The Mississippi Division of Medicaid's preferred drug list (PDL) covers levothyroxine sodium tablets, including the generic and Synthroid, but Tirosint's gel capsule formulation is excluded from the covered formulary. A prior authorization request is technically possible, but Mississippi Medicaid has not published a pathway for approval of Tirosint under its hypothyroidism benefit category.

Patients enrolled in Mississippi Medicaid who require a gel capsule or liquid levothyroxine formulation for documented malabsorption or excipient sensitivity have three practical options. First, they may attempt a prior authorization citing the clinical literature on absorption failure with tablets, though approval is not guaranteed and no published approval rate data exists for this indication in Mississippi. Second, they may pay cash for Tirosint at the full $230 monthly price. Third, and most practically for Medicaid-enrolled patients, they may obtain a prescription for a compounded levothyroxine gel capsule from a licensed 503A pharmacy (discussed in the section below).

The Centers for Medicare and Medicaid Services guidance on state Medicaid formulary requirements notes that states retain discretion to exclude brand-name drugs that have covered generic equivalents. Mississippi exercises that discretion for Tirosint.

Mississippi's Medicaid population faces disproportionate thyroid disease burden. CDC national data shows that hypothyroidism prevalence correlates with obesity rates, and Mississippi's adult obesity prevalence of 40.8% (the highest in the nation) suggests a large population of undertreated thyroid patients for whom cost is a real barrier. Untreated or undertreated hypothyroidism raises LDL cholesterol, worsens insulin resistance, and contributes to cardiovascular risk, as detailed in a 2019 review in the Journal of the American College of Cardiology.

Which Commercial Insurance Plans Cover Tirosint in Mississippi?

Commercial insurance coverage for Tirosint in Mississippi varies by plan and tier. No Mississippi-specific formulary mandate requires coverage of Tirosint, so each insurer determines placement independently.

Blue Cross Blue Shield of Mississippi lists Tirosint as a Tier 3 (non-preferred brand) drug on most of its individual and employer plans, meaning patients pay 40% to 50% coinsurance after meeting a deductible. For a $230 list-price drug, that translates to $92 to $115 per month even with insurance, before the deductible is met. United Healthcare and Aetna plans available in Mississippi generally place Tirosint on Tier 3 or Tier 4, depending on the specific plan design. Humana Medicare Advantage plans in Mississippi typically do not cover Tirosint on their Part D formularies because no FDA-approved generic gel capsule forces formulary inclusion.

Patients with employer-sponsored insurance should check their Summary of Benefits and Coverage (SBC) or call the member services number on their insurance card to confirm Tirosint's tier and whether a step-therapy or prior authorization requirement applies. Step-therapy requirements, where a patient must fail a tablet formulation before the insurer covers Tirosint, are common and can be contested by the prescribing physician with clinical documentation.

The American Thyroid Association's 2014 hypothyroidism guidelines state that "in patients who continue to have symptoms on levothyroxine tablets and are suspected of having absorption problems, a change to liquid or gel capsule preparations should be considered," which provides a usable basis for prior authorization appeals.

How the IBSA Savings Card Works in Mississippi

IBSA, Tirosint's manufacturer, operates a copay savings card program for commercially insured patients. The card is not available to patients using federal or state government insurance, including Medicare, Medicaid, Tricare, or CHIP. Mississippi Medicaid patients are therefore excluded.

For eligible commercially insured patients in Mississippi, the IBSA savings card can reduce the monthly out-of-pocket cost to as low as $0 for qualifying plans, though the typical reduction brings the patient copay to $25 to $60 per month depending on the insurance tier. The card covers the gap between the patient's copay and a defined threshold.

Enrollment is available directly through the IBSA website or by asking the prescribing pharmacist. The card must be presented at the time of dispensing and cannot be applied retroactively to a prescription already filled and paid. Cards are re-issued annually and require re-enrollment each calendar year.

Patients without commercial insurance, including uninsured and Medicaid-only patients, do not qualify for the IBSA savings card. For those patients, compounded levothyroxine (see below) or manufacturer-sponsored patient assistance programs represent the remaining cost-reduction options. IBSA's patient assistance program for uninsured patients with documented financial hardship can be reached through the prescriber's office and may provide Tirosint at no cost for qualifying individuals.

Details of the savings program align with standard manufacturer assistance structures as described in NCI resources on financial assistance for prescription drugs.

Is Compounded Levothyroxine Gel Capsule Legal in Mississippi?

Yes. Licensed 503A compounding pharmacies in Mississippi may legally compound levothyroxine gel capsules or oral liquid preparations for individual patients with a valid prescription. The FDA's 503A compounding framework permits state-licensed pharmacies to prepare patient-specific compounded drugs when a commercially available product does not meet the patient's clinical needs.

Mississippi's State Board of Pharmacy licenses and regulates 503A pharmacies operating within the state. Out-of-state 503A pharmacies may also ship compounded levothyroxine to Mississippi patients, provided the compounding pharmacy holds a non-resident pharmacy permit from the Mississippi Board of Pharmacy and meets all 503A federal requirements.

The clinical rationale for compounded levothyroxine gel capsules mirrors that of Tirosint: patients who cannot absorb standard tablet excipients, or who require dose strengths not commercially available (such as pediatric micro-dosing or doses between standard commercial strengths), may benefit from a compounded preparation. A compounded levothyroxine gel capsule or oral liquid is not the same as FDA-approved Tirosint. Compounded preparations do not undergo the same manufacturing controls, stability testing, or bioavailability studies as FDA-approved drugs. Clinicians should monitor TSH at 6 to 8 weeks after any formulation change, as recommended in the American Thyroid Association 2014 guidelines.

Cost is a meaningful advantage. Compounded levothyroxine gel capsules at 503A pharmacies accessible to Mississippi patients are priced in the $25 to $60 per month range in 2026, compared to $230 for brand Tirosint, representing a savings of $170 to $205 per month. For Medicaid patients who receive no coverage for Tirosint, this cost differential is clinically meaningful for long-term adherence.

A 2019 systematic review in Frontiers in Endocrinology examining levothyroxine bioavailability across formulations noted that liquid and gel capsule preparations showed 10% to 22% higher peak serum T4 concentrations compared to tablets in patients with documented gastric acid suppression. That analysis is available via PubMed.

Can Mississippi Patients Get a Tirosint Prescription via Telehealth?

Telehealth prescribing of Tirosint is fully legal in Mississippi. The Mississippi State Board of Medical Licensure permits licensed physicians and advanced practice providers to conduct synchronous telemedicine visits and prescribe non-controlled prescription medications, including levothyroxine products. A valid prescriber-patient relationship must be established via a real-time audio-visual encounter before the initial prescription is issued.

Mississippi adopted telehealth parity law provisions that require commercial insurers to cover telehealth services at the same rate as in-person services for covered conditions. Hypothyroidism management and thyroid hormone replacement prescribing fall within covered telehealth categories for most major plans operating in the state.

For rural Mississippi patients, telehealth access to endocrinology or primary care thyroid management is particularly relevant. Mississippi has 82 counties; only 17 contain endocrinologists, according to Mississippi State Department of Health workforce data. Telehealth visits with HealthRX clinicians licensed in Mississippi allow patients statewide to receive thyroid evaluation, TSH and free T4 lab review, and Tirosint prescriptions sent electronically to any Mississippi retail or compounding pharmacy.

After a telehealth prescription is issued, lab follow-up at 6 to 8 weeks is standard of care regardless of formulation, consistent with guidance from the American Association of Clinical Endocrinology (AACE).

Clinical Situations Where Tirosint Is Prescribed Over Generic Tablets

Tirosint is not a first-line choice for all hypothyroid patients. Prescribers typically consider the gel capsule formulation in specific clinical scenarios, each of which has published supporting evidence.

Achlorhydria and hypochlorhydria. Gastric acid is required for optimal tablet dissolution and T4 absorption. Patients with atrophic gastritis, Helicobacter pylori infection, or long-term proton pump inhibitor (PPI) use show measurably reduced levothyroxine tablet absorption. Vita et al. (2014) demonstrated TSH normalization after switching PPI-using patients from tablets to gel capsules, with mean TSH decreasing from 5.8 mIU/L on tablets to 2.3 mIU/L on gel capsules at equivalent doses (P<0.01). Full study: PubMed 25168316.

Malabsorption syndromes. Celiac disease, inflammatory bowel disease, and bariatric surgery (particularly Roux-en-Y gastric bypass) reduce small intestinal absorption surface area and impair T4 uptake from tablets. A 2020 study in Nutrients (N=60, celiac patients on a gluten-free diet) found that 38% still required levothyroxine dose increases when on tablets, while switching to liquid formulation stabilized TSH without dose escalation in 71% of those patients. PubMed citation for comparison data.

Excipient sensitivity. Patients with documented allergies or intolerances to tablet binders (lactose in some formulations, acacia, talc) may tolerate Tirosint's four-ingredient formula better. This is less common but clinically documented in published case series.

Inconsistent TSH despite tablet adherence. When a patient reports consistent dosing but TSH remains erratic across serial measurements, a formulation switch is a reasonable diagnostic and therapeutic step before attributing variability to non-adherence.

The decision framework above distinguishes situations where Tirosint offers a measurable clinical advantage from situations where a standard generic tablet is appropriate and far less expensive. Not every Mississippi patient with hypothyroidism needs Tirosint. Patients with straightforward primary hypothyroidism, no gastrointestinal comorbidities, no excipient sensitivities, and stable TSH on generic tablets have no evidence-based reason to switch.

Absorption Timing and Administration: What Mississippi Patients Should Know

Levothyroxine gel capsules, including Tirosint, should be taken on an empty stomach, 30 to 60 minutes before the first meal or other medications. Calcium carbonate, ferrous sulfate, sucralfate, and aluminum-containing antacids each reduce levothyroxine absorption by 20% to 40% when taken within 4 hours of dosing, as documented in the Tirosint FDA prescribing label.

Coffee, including black coffee, reduces levothyroxine tablet absorption by approximately 30% when consumed simultaneously. A 2008 study in Thyroid (N=8) found this effect is less pronounced with liquid formulations, suggesting gel capsules may offer some protection against coffee-related absorption interference. Mississippi patients who habitually take their thyroid medication with morning coffee should discuss switching to the gel capsule or liquid formulation with their prescriber.

TSH should be checked 6 to 8 weeks after any formulation change, including switching from generic tablet to Tirosint or from Tirosint to a compounded preparation. The 2021 AACE clinical practice guidelines for hypothyroidism set the TSH target for most adults at 0.5 to 2.5 mIU/L, with adjustments for age (TSH targets shift upward for patients over 70) and pregnancy (TSH targets below 2.5 mIU/L in the first trimester per ACOG Practice Bulletin 223).

What Mississippi Patients Pay Out of Pocket: A Side-by-Side Cost Table

| Scenario | Estimated Monthly Cost (MS, 2026) | |---|---| | Brand Tirosint, no insurance, no card | $230 | | Brand Tirosint, Tier 3 commercial insurance (after deductible) | $92 to $115 | | Brand Tirosint, IBSA savings card (commercially insured) | $0 to $60 | | Brand Tirosint, Mississippi Medicaid | Not covered | | Compounded levothyroxine gel cap, 503A pharmacy | $25 to $60 | | Generic levothyroxine tablet, GoodRx | $4 to $25 |

These ranges reflect 2026 pharmacy survey data and IBSA published program parameters. Individual pharmacy dispensing fees in Mississippi add $1 to $8 per fill and are included in the estimates above. Rural Mississippi pharmacies (particularly in the Delta region) may charge slightly higher dispensing fees than urban Flowood or Ridgeland pharmacies.

For patients paying cash for Tirosint at $230 per month, the annual cost is $2,760. At $60 per month for a compounded gel cap, the annual cost is $720. Over a patient's lifetime on thyroid replacement therapy (often decades), that difference compounds substantially.

The American Heart Association's 2023 cardiovascular disease cost and statistics report documents that medication non-adherence driven by out-of-pocket cost is one of the leading causes of preventable cardiovascular events in patients with chronic conditions including hypothyroidism-associated dyslipidemia.